Additional biomarkers for pathological complete response in triple negative breast cancer.
作者信息
Weem Khui Wei, Tong Kah Cheong
机构信息
Manchester Royal Infirmary Hospital, Oxford Road, Manchester M13 9WL, UK.
Acute Medical Unit, Stepping Hill Hospital, Stockport, UK.
出版信息
Ther Adv Med Oncol. 2024 Jul 27;16:17588359241267148. doi: 10.1177/17588359241267148. eCollection 2024.
Abstract
摘要
相似文献
1
Additional biomarkers for pathological complete response in triple negative breast cancer.三阴性乳腺癌病理完全缓解的其他生物标志物。
Ther Adv Med Oncol. 2024 Jul 27;16:17588359241267148. doi: 10.1177/17588359241267148. eCollection 2024.
2
Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.新辅助治疗后不同乳腺癌肿瘤免疫微环境表型的比较。
Cancer Med. 2023 Feb;12(3):2906-2917. doi: 10.1002/cam4.5207. Epub 2022 Sep 8.
3
Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.基于PD-1/PD-L1免疫检查点阻断的转移性三阴性乳腺癌联合免疫疗法
Int Immunopharmacol. 2022 Dec;113(Pt B):109444. doi: 10.1016/j.intimp.2022.109444. Epub 2022 Nov 16.
4
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.早期三阴性乳腺癌中靶向PD-1/PD-L1的免疫疗法
J Pers Med. 2023 Mar 15;13(3):526. doi: 10.3390/jpm13030526.
5
Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.PD-1/PD-L1 抑制剂在三阴性乳腺癌中的疗效和安全性：系统评价和荟萃分析。
Acta Oncol. 2022 Sep;61(9):1105-1115. doi: 10.1080/0284186X.2022.2106795. Epub 2022 Aug 8.
6
New strategies for the management of triple-negative breast cancer.三阴性乳腺癌的治疗新策略。
Curr Opin Obstet Gynecol. 2024 Feb 1;36(1):40-44. doi: 10.1097/GCO.0000000000000927. Epub 2023 Dec 8.
7
Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.程序性死亡配体 1（PD-L1）表达预测三阴性乳腺癌新辅助化疗的反应：系统评价和荟萃分析。
Biomarkers. 2022 Dec;27(8):764-772. doi: 10.1080/1354750X.2022.2112614. Epub 2022 Aug 22.
8
Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.三阴性乳腺癌中影响肿瘤浸润淋巴细胞和 PD-L1 表达模式的基因组改变。
J Natl Cancer Inst. 2023 Dec 6;115(12):1586-1596. doi: 10.1093/jnci/djad154.
9
Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer.用于预测原发性三阴性乳腺癌免疫治疗反应的基因表达分类器的构建与验证
Commun Med (Lond). 2023 Jul 10;3(1):93. doi: 10.1038/s43856-023-00311-y.
10
Clinical characteristics associated with efficacy and prognosis among patients treated with PD-1/PD-L1 inhibitors for early-stage triple-negative breast cancers: A meta-analysis.PD-1/PD-L1 抑制剂治疗早期三阴性乳腺癌患者的疗效和预后相关的临床特征：一项荟萃分析。
Crit Rev Oncol Hematol. 2024 Apr;196:104309. doi: 10.1016/j.critrevonc.2024.104309. Epub 2024 Feb 28.
本文引用的文献
1
Assessment of novel prognostic biomarkers to predict pathological complete response in patients with non-metastatic triple-negative breast cancer using a window of opportunity design.利用机会窗设计评估新型预后生物标志物以预测非转移性三阴性乳腺癌患者的病理完全缓解情况。
Ther Adv Med Oncol. 2024 May 24;16:17588359241248329. doi: 10.1177/17588359241248329. eCollection 2024.
2
Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.三阴性乳腺癌与新辅助化疗反应的预测标志物：一项系统综述。
Int J Mol Sci. 2023 Feb 3;24(3):2969. doi: 10.3390/ijms24032969.
3
A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.BRCA1/2 突变预测三阴性乳腺癌铂类化疗效果的系统评价和荟萃分析。
Breast. 2022 Dec;66:31-39. doi: 10.1016/j.breast.2022.08.012. Epub 2022 Sep 2.
4
Triple-negative breast cancer: promising prognostic biomarkers currently in development.三阴性乳腺癌：目前正在开发的有前途的预后生物标志物。
Expert Rev Anticancer Ther. 2021 Feb;21(2):135-148. doi: 10.1080/14737140.2021.1840984.
5
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.三阴性乳腺癌中 CD73 的临床意义：III 期临床试验的多重分析。
Ann Oncol. 2018 Apr 1;29(4):1056-1062. doi: 10.1093/annonc/mdx730.
6
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.BRCA1 突变患者中三阴性乳腺癌的特征：一项基于人群的年轻女性研究结果。
J Clin Oncol. 2011 Nov 20;29(33):4373-80. doi: 10.1200/JCO.2010.33.6446. Epub 2011 Oct 17.
Zotero 插件